NCT03069469: Study of DCC-3014 in Patients With Advanced Malignancies

NCT03069469
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active CNS metastases
https://ClinicalTrials.gov/show/NCT03069469

Comments are closed.

Up ↑